1. Home
  2. GENC vs TLSA Comparison

GENC vs TLSA Comparison

Compare GENC & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gencor Industries Inc.

GENC

Gencor Industries Inc.

HOLD

Current Price

$14.53

Market Cap

232.2M

Sector

Industrials

ML Signal

HOLD

Logo Tiziana Life Sciences Ltd.

TLSA

Tiziana Life Sciences Ltd.

HOLD

Current Price

$1.31

Market Cap

155.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GENC
TLSA
Founded
N/A
2013
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Construction/Ag Equipment/Trucks
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
232.2M
155.2M
IPO Year
1995
2017

Fundamental Metrics

Financial Performance
Metric
GENC
TLSA
Price
$14.53
$1.31
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$16.00
N/A
AVG Volume (30 Days)
24.8K
100.8K
Earning Date
05-18-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
8.08
N/A
EPS
0.23
N/A
Revenue
$48,943,000.00
N/A
Revenue This Year
$6.36
N/A
Revenue Next Year
$8.32
N/A
P/E Ratio
$63.48
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.80
$0.73
52 Week High
$17.40
$2.60

Technical Indicators

Market Signals
Indicator
GENC
TLSA
Relative Strength Index (RSI) 44.33 41.88
Support Level $13.56 N/A
Resistance Level $14.68 $1.61
Average True Range (ATR) 0.54 0.11
MACD -0.19 -0.01
Stochastic Oscillator 25.09 20.27

Price Performance

Historical Comparison
GENC
TLSA

About GENC Gencor Industries Inc.

Gencor Industries Inc and its subsidiaries are a manufacturer of heavy machinery used in the production of highway construction materials and environmental control equipment. The Company's products are manufactured in the United States and sold through a combination of Company sales representatives and independent dealers and agents. The Company has one reporting segment, equipment for the highway construction industry. The Company's principal core products include asphalt pavers, hot mix asphalt plants, combustion systems, and fluid heat transfer systems. It operates in the United States, Canada, and other foreign countries, with the majority of revenue coming from the United States.

About TLSA Tiziana Life Sciences Ltd.

Tiziana Life Sciences Ltd is a clinical stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, Alzheimer's, and ALS. Its flagship immunotherapeutic candidate, Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody, is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's and other CNS indications.

Share on Social Networks: